NCT07022457 2026-04-13
UK-EnBiRiM
Pierre Fabre Ltd
Active not recruiting
Clinical Trials
17 trialsNCT04657991 2026-04-07
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT05260684 2025-03-06
OCEANMIST
Pfizer
Completed
NCT01436656 2024-10-28
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Pfizer
Phase 1 Completed
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT05003622 2024-06-24
OCEANI
Pierre Fabre Medicament
Phase 1 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT05270044 2023-11-22
COLUMBUS-AD
Pierre Fabre Medicament
Phase 3 Active not recruiting
NCT03911869 2023-05-31
POLARIS
Pfizer
Phase 2 Terminated
NCT03878719 2023-04-03
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Pfizer
Phase 1 Terminated
NCT04759846 2023-02-21
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Pierre Fabre Medicament
Phase 1 Withdrawn
NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04045691 2021-01-19
BERING
Pierre Fabre Pharma GmbH
Recruiting
NCT01820364 2017-01-09
LOGIC
Array BioPharma
Phase 2 Terminated
NCT01777776 2016-09-13
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Array BioPharma
Phase 1/2 Terminated